-
Mashup Score: 0Breaking Down the Practice of Bagging | ASH Clinical News | American Society of Hematology - 24 hour(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. Most drugs administered via infusion have traditionally been purchased by the treating physician’s office or hospital and administered to patients in the corresponding medical setting. This method, commonly referred to as “buy-and-bill,” is typically covered by a patient’s medical insurance. In 2021, the specialty drug market, which includes oral chemotherapy drugs, was estimated to represent about 50% of total drug spending in
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. New research supports the incorporation of white blood cell (WBC) count into polycythemia vera (PV) risk-stratification for thrombosis. The findings by Aaron T. Gerds, MD, MS, associate professor of medicine at Cleveland Clinic in Ohio, and colleagues also indicate the importance of controlling both hematocrit and WBC count in disease management. They published the results of the REVEAL (pRospective obsErvational study of patients
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1New ASH Academy on Demand Resources Available | ASH Clinical News | American Society of Hematology - 10 day(s) ago
ASH Academy on Demand is a key resource provided by the American Society of Hematology (ASH) to support members’ continuous education needs and professional development. Offerings include simulations, webcasts, self-paced programs, and online courses, all developed by subject matter experts, as well as opportunities for members to earn credit through maintenance of certification and continuing medical education activities. The ASH Academy catalog is always growing to better meet members’ needs — read on
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2New ASH Academy on Demand Resources Available | ASH Clinical News | American Society of Hematology - 13 day(s) ago
ASH Academy on Demand is a key resource provided by the American Society of Hematology (ASH) to support members’ continuous education needs and professional development. Offerings include simulations, webcasts, self-paced programs, and online courses, all developed by subject matter experts, as well as opportunities for members to earn credit through maintenance of certification and continuing medical education activities. The ASH Academy catalog is always growing to better meet members’ needs — read on
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1ASH Clinical News: May 2024 From the Desk Of... - 15 day(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, previews the upcoming May issue of the magazine. Highlights include a feature on the practice of “bagging”…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4In Full Bloom: A Closer Look at Open-Access Publishing | ASH Clinical News | American Society of Hematology - 18 day(s) ago
Naseema Gangat, MBBS, is a professor of medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota. In the last two decades, open-access publishing has become mainstream and is now like a rose in full bloom within the scientific world. Like Queen Mary’s Garden in London’s Regent’s Park, which boasts about 12,000 roses and is free of charge, the number of open-access journals that provide free online content to readers has blossomed to more than 20,000. 1 Roses at Queen Mary’s Garden in
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Apixaban No Better Than Aspirin for Treatment of Embolic Stroke of Undetermined Source | ASH Clinical News | American Society of Hematology - 20 day(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. Use of the direct oral anticoagulant (DOAC) apixaban was not superior to cardiac monitoring-guided aspirin for the prevention of new ischemic lesions in a patient population with an enriched embolic stroke of undetermined source (ESUS), according to results of the ATTICUS study published in NEJM Evidence. In a multicenter, open-label, randomized study of patients with ESUS and at least one predictive factor for atrial fibrillation
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Pulling Back the Curtain: Ruemu Ejedafeta Birhiray, MD | ASH Clinical News | American Society of Hematology - 26 day(s) ago
Mary Ellen Schneider is a medical journalist based in Setauket, New York. Ruemu E. Birhiray, MD, is a hematologist/oncologist and clinical investigator at Hematology Oncology of Indiana in Indianap olis and president and CEO of Indy Hematology Education. He is also a clinical professor of medicine at Marian University College of Osteopathic Medicine in Indianapolis. Dr. Birhiray has published research on immunotherapy, lymphomas, and bone marrow transplantation, and recently authored a practical strategy
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3High-Dose Oral Vitamin A Before HCT May Reduce GVHD in Children | ASH Clinical News | American Society of Hematology - 28 day(s) ago
Katie Robinson is a medical writer based in New York. Compared with placebo, a high dose of oral vitamin A given before a hematopoietic cell transplant (HCT) did not reduce the incidence of acute graft-versus-host disease (GVHD) in children. However, the results of a phase II study published in Blood found that high-dose vitamin A given pre-HCT reduced chronic GVHD in this population and reduced acute gastrointestinal (GI) GVHD in an as-treated analysis. 1 Vitamin A maintains immune homeostasis in the
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2FDA, EMA to Review Hemophilia Treatment | ASH Clinical News | American Society of Hematology - 29 day(s) ago
The U.S. Food and Drug Administration (FDA) accepted Pfizer’s Biologics License Application for marstacimab as treatment for hemophilia A or hemophilia B in patients without inhibitors to factor VIII or factor IX. The Prescription Drug User Fee Act action date is set for the fourth quarter of 2024. Marstacimab is a human monoclonal immunoglobulin G isotype. It works by targeting the Kunitz 2 domain of tissue factor pathway inhibitor. The treatment is being investigated as a prophylactic treatment to
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
Brown bagging may be a great way to save money in the cafeteria, but now payers are trying to do the same in the infusion room. In this month’s feature article, ACN explores the ongoing controversy surrounding this practice. https://t.co/alCcsglGho